Caspase 3 as a Novel Marker to Distinguish Chromophobe Renal Cell Carcinoma from Oncocytoma

Pathology oncology research: POR

article

Kowalewski, Adam¹  Szylberg, Łukasz¹  Tyloch, Janusz²  Antosik, Paulina¹  Neska-Długosz, Izabela¹  Frąckowski, Łukasz²  Tyloch, Dominik²  Purpurowicz, Piotr²  Grzanka, Dariusz¹ 

[1]Department of Clinical Pathomorphology, Nicolaus Copernicus University in Torun

[2]Department of General and Oncologic Urology, Nicolaus Copernicus University

关键词: Chromophobe;    ChRCC;    Oncocytoma;    Caspase 3;    CASP3;    Cyclin D1;    p16;    Survivin;    CD138;    Ki-67;   

DOI  :  10.1007/s12253-018-0548-8

来源: Springer

【 摘 要 】

Despite advances in our understanding of the biology of chromophobe renal cell carcinoma (ChRCC) and renal oncocytoma (RO), the differential diagnosis among these tumors remains one of the most problematic in renal pathology. Today, CK7 is the most recommended marker to distinguish these entities, however it appears insufficiently accurate by itself. This study aimed to find an easily accessible IHC stain that might out-compete CK7 in this field. Expressions of CK7, cyclin D1, p16, survivin, CD138, Ki-67 and caspase 3 (CASP3) were analyzed in a total of 27 cases (20 ROs and 7 ChRCCs). Immunoreactivity was assessed based on a combined score of the extent and intensity of staining. Compared to RO, a higher percentage of the total ChRCCs stained positive for CK7 (67% vs. 22%, respectively) and CASP3 (86% vs. 25%) (P < 0.005). The differences in staining with cyclin D1, p16, survivin, CD138 and Ki-67 turned out to be statistically insignificant in differentiating ChRCC from RO. CASP3 is a promising marker in distinguishing ChRCC from RO and may represent an alternative for CK7. Cyclin D1, p16, survivin, CD138 and Ki-67 cannot be used to distinguish these neoplasms.

【 授权许可】

Unknown